# FK506 (Tacrolimus) in Pulmonary Arterial Hypertension

> **NCT01647945** · PHASE2 · COMPLETED · sponsor: **Edda Spiekerkoetter** · enrollment: 23 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Placebo
- **DRUG:** FK506 level < 2 ng/ml
- **DRUG:** FK506 level 2-3 ng/ml
- **DRUG:** FK506 level 3-5 ng/ml

## Key facts

- **NCT ID:** NCT01647945
- **Lead sponsor:** Edda Spiekerkoetter
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2014-05
- **Final completion:** 2014-08
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2016-10-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01647945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01647945, "FK506 (Tacrolimus) in Pulmonary Arterial Hypertension". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01647945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*